. Through this transcriptional network, NRF2 is able to coordinate a multifaceted response to diverse forms of stress, enabling maintenance of a stable internal environment.
In 1999, Kelch-like ECH-associated protein 1 (KEAP1) was identified as a repressor of NRF2 (REf.
),
and a further 5 years elapsed before it was reported to be an E3 ubiquitin ligase substrate adaptor that targets NRF2 for rapid proteasomal degradation [6] [7] [8] . Thus, KEAP1 ensures that under unstressed conditions, NRF2 is a protein of low abundance with a limited half-life of only about 15-40 min, depending on the cell type. Importantly, however, KEAP1 contains several highly reactive cysteines that, upon modification by electrophilic molecules, prevent it from targeting NRF2 for proteasomal degradation, thereby resulting in rapid nuclear accumulation of NRF2 protein upon redox stress and, following dimerization with small musculoaponeurotic fibrosarcoma oncogene homologue (sMAF) proteins, induction of ARE-containing genes by NRF2-sMAF 9, 10 . It is now widely recognized that because of the versatile and comprehensive cytoprotective roles of the proteins encoded by NRF2-target genes, including antioxidant, detoxification and anti-inflammatory proteins, a functional NRF2-KEAP1 axis is essential for protection against a plethora of diseases that have oxidative stress and inflammation as underlying pathological features. These include metabolic, inflammatory and autoimmune disorders; diseases of the lung, liver, kidney, gastrointestinal (GI) tract and cardiovascular system; and neurological conditions 9, 11 . The experimental evidence for the protective effects of NRF2 in these non-neoplastic diseases is discussed later in this Review. We also address the role of NRF2 in cancer, which is a matter of intense research 12 . A 3D reconstruction of the KEAP1 dimer obtained by single-particle electron microscopy shows that the protein has a forked-stem structure comprising two large spheres that enclose the intervening region (IVR), Kelch, and carboxy-terminal domains, whereas dimerization is mediated by the BTB domain 13 ( fig. 1a ). Bearing in mind that KEAP1 contains a number of distinct and autonomously functioning cysteine sensors (C151, C226, C273, C288 and C613) [14] [15] [16] , the existing evidence suggests that NRF2 and KEAP1 integrate nitric oxide, Zn 2+ and alkenal signalling with redox signalling and that together they also provide a mechanism that probably evolved,
Antioxidant response element
(ARE). Specific DNA sequences that are present in the promoter regions of transcription factor Nf-E2 p45-related factor 2 (NRf2)-target genes. The ARE was discovered before NRf2, and its name originates from the fact that it was first identified in the promoter regions of genes that are induced by phenolic antioxidants.
Xenobiotic biotransformation
The metabolic conversion of exogenous chemicals into water-soluble compounds to facilitate excretion, primarily via urine or bile.
Redox stress
An imbalance between oxidants and antioxidants in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage.
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
at least in part, to allow rapid adaptation to exposure to phytochemicals encountered in the diet. Many plantderived electrophilic xenobiotics activate the NRF2-KEAP1 axis to elicit cytoprotective responses, with the highly reactive cysteines in KEAP1 acting as the immediate sensors [17] [18] [19] . The high reactivity of these sensors with electrophiles allows for therapeutic KEAP1 targeting in the absence of nonspecific thiol modifications ( fig. 1b) . Therefore, many naturally occurring inducers of NRF2-target genes have been described 20 , and new inducing agents continue to be discovered.
Although a substantial number of academic laboratories have been involved in the identification of NRF2 activators, historically the engagement of pharmaceutical companies in this exciting and promising field has been fairly low key. This possible reticence of industry to consider the NRF2-KEAP1 axis as a valuable drug target may be due in part to its wide spectrum of biochemical activities, beyond merely controlling antioxidant systems, which are regulated either directly or indirectly by NRF2. The diverse direct and indirect effects of NRF2 activators are sometimes interpreted as evidence of nonspecific effects. However, the evolution of several distinct thiol-based redox switches within KEAP1 that allow mammalian species to adapt to a wide spectrum of phytochemicals provides a rationale for changing the perception that activation of NRF2 elicits certain 'off-target' effects and adopting a broader view that activation of NRF2 elicits beneficial 'multi-target' cytoprotective effects 11 . In particular, the multi-target benefits of NRF2 activation include maintenance of redox signalling, enhanced xenobiotic biotransformation, control and resolution of inflammation, suppression of gluconeogenesis and hepatic lipogenesis, support of proteostasis and suppression of fibrosis 9 . In this context, it is noteworthy that most chronic diseases, particularly those confined to the aged population, do not have a unique aetiology, nor do they exhibit a single pathophenotype, and as such they may be most effectively treated with drugs that activate NRF2. Indeed, stimulation of broad cytoprotective mechanisms upon NRF2 activation is less likely to be effectively overwhelmed or circumvented by pathogenic processes than are more specifically targeted therapeutic interventions.
This expanded recognition of NRF2 as a potential drug target has sparked the interest of the pharmaceutical industry and led to a substantial investment in the clinical development of NRF2 modulators 21 . The NRF2 activator dimethyl fumarate (DMF; trade names, Fumaderm or Tecfidera) is now clinically used to treat psoriasis and remitting-relapsing multiple sclerosis (MS) (TAblE 1) , and its current distribution remains a hallmark that other pharmaceutical companies hope to achieve. Currently, a number of NRF2 activators of several distinct chemical classes are at various stages of clinical development, such as the KEAP1 cysteine-targeting fumaric acid derivatives, the isothiocyanate sulforaphane (SFN; 4-methylsulfinylbutyl isothiocyanate), cyanoenone triterpenoids, nitro fatty acids and hydroxylamine. Additional drug candidates include non-electrophilic compounds that disrupt the NRF2-KEAP1 protein-protein interactions (PPIs) as well as molecules with KEAP1-independent modes of action. Inhibitors of NRF2 are also being pursued but are not yet in clinical trials. This Review provides an overview of these drug candidates and highlights the unusual nature and the critical importance of context for targeting the NRF2-KEAP1 axis. The physiological roles of NRF2 in cellular redox, metabolic and protein homeostasis, and in resolution of inflammation are described, and experimental evidence for the protective role of NRF2 in non-neoplastic disease is presented. The advantages and limitations of the various small-molecule pharmacological modulators of NRF2 activity that are in clinical development are assessed. Finally, ongoing challenges associated with the development of NRF2 modulators, including target specificity, pharmacodynamic assessment, bioavailability, efficacy and safety are highlighted.
Physiological roles of the NRF2-KEAP1 axis Redox, metabolic and protein homeostasis. Since its initial discovery in the participation of biotransformation reactions, in which it regulates the expression of certain cytochrome P450 oxidoreductases, conjugating enzymes and ABC transporters (TAblE 2) , it has become increasingly apparent that NRF2 is involved in control of the intracellular redox environment, culminating in recognition of the NRF2-KEAP1 axis as a 'thiol-driven master switch' that is used for 'system-wide oxidative stress responses' 22 . NRF2 regulates the expression of the four genes (glucose 6-phosphate dehydrogenase, 6-phospho gluconate dehydrogenase, malic enzyme 1 and isocitrate dehydrogenase 1) involved in the generation of NADPH, the critical cofactor that fuels antioxidant reactions [23] [24] [25] [26] . The supply of this reducing equivalent is further used by a plethora of redox reactions, many of which are also regulated by NRF2. Thus, NRF2 regulates the expression of critical enzymes involved in the synthesis and use of the redox buffer reduced glutathione (GSH; the oxidized form of which is GSSG), such as the catalytic and modulator subunits of glutamate-cysteine ligase, glutathione reductase, glutathione peroxidase and several glutathione S-transferases 4 . Moreover, many ancillary proteins within the redoxin family, such as thioredoxin, thioredoxin reductase, peroxiredoxin Electrophiles Electron-deficient atoms or molecules that take an electron pair from a donor molecule to form a covalent bond.
Gluconeogenesis
Metabolic process that generates glucose from noncarbohydrate carbon substrates, such as lactate, glycerol and glucogenic amino acids.
and sulfiredoxin, are all regulated by NRF2 and provide compartmentalized sensing and signal transduction of regional production of reactive oxygen species (ROS; that is, hydrogen peroxide (H 2 O 2 ), the hydroxyl radical and the superoxide radical) [27] [28] [29] . In addition to these direct effects on redox status, NRF2 regulates genes encoding enzymes that prevent quinones from participating in redox cycling reactions and glutathione depletion (by NAD(P)H:quinone oxidoreductase 1 (NQO1)) or that are involved in the indirect production of bilirubin (haem oxygenase 1 (HMOX1) and biliverdin reductase (BVR)), which is the most potent nonpolar physiological antioxidant 30 . Finally, through crosstalk with the pentose phosphate pathway and glycolysis, NRF2 affects intermediary metabolism and increases the availability of substrates and reducing equivalents for the mitochondrial respiratory chain 31 as well as for maintaining integrity of mitochondrial DNA (mtDNA) 32 . NRF2 participates in the clearance of oxidized, or otherwise damaged, proteins and organelles during redox alterations or nutritional starvation. Thus, the autophagy transporter ubiquitin-binding protein p62 (encoded by SQSTM1), which interacts with ubiquitylated cargo via its ubiquitin association (UBA) domain and recruits them into the autophagosome via its LC3-interacting motif, is an NRF2 transcriptional target 33, 34 . In addition, KEAP1 binds to p62 (REfS 33, 35 ), and a recent study has found that KEAP1-CULLIN 3 (CUL3) ubiquitylates p62 at K420 within its UBA domain, thereby facilitating the sequestration activity of p62 (REf.
36
). Within its primary structure, p62 contains an ETGE-like motif, STGE, which upon phosphorylation by mTORC1 generates the recognition site for docking to KEAP1 (REf.
37
). Then, KEAP1 is transported to the autophagosome for degradation, thus allowing accumulation of NRF2 (REf.
38
). Moreover, several autophagy genes appear to contain ARE sequences in their promoter regions, and it has been reported that NRF2 activates both chaperone-mediated autophagy 39 and macroautophagy 40, 41 . Other roles of NRF2 in proteostasis under oxidative conditions are demonstrated by its activation by the unfolded protein response 42, 43 and its ability to regulate proteasome subunit expression 44, 45 . At least in brain and blood, the abundance of mRNA encoding NRF2 is higher than that for KEAP1 (fig. 2) ; by contrast, the half-life of the KEAP1 protein is longer than that of NRF2 (TAblE 2) . These observations highlight the different turnover rates of the two proteins -slow for KEAP1 and fast for NRF2. Moreover, although NRF2 and KEAP1 are ubiquitously expressed, specific cell types are predominantly in charge of homeostatic adaptations and present different levels of expression ( fig. 2) . Thus, monocytes and neutrophils exhibit the highest levels of NRF2 among blood cells, suggesting an immunomodulatory effect of the innate immune system (see below). In the brain, crosstalk between astrocytes and neurons couples intermediate metabolism with redox homeostasis, at least in part through NRF2 (REf.
46
). Moreover, glutamatergic neurotransmission in neurons leads to production of ROS that are controlled by the neuronal GSH pool. When this pool is low, neighbouring astrocytes contribute to its restoration by providing neurons with the GSH precursors glycine, glutamate/glutamine and cysteine 47 . Not surprisingly, NRF2 levels are high in astrocytes ( fig. 2) . Moreover, microglia as part of the monocyte lineage express high levels of NRF2 compared with neurons. 241 inserted for illustrative purposes. The reactive cysteines C151 and C613 are shown as blue spheres. The precise positions of C226, C278 and C288 are not known, but they are all located in the intervening region (IVR) domain of KEAP1. The KEAP1 homodimer binds to transcription factor NF-E2 p45-related factor 2 (NRF2) at two motifs with low affinity (29-DLG-31) and high affinity and targets this transcription factor for ubiquitylation and proteasomal degradation. Current strategies to disrupt this interaction include electrophiles that chemically modify sulfhydryl groups of at least cysteines C151, C273 and C288 in KEAP1 and protein-protein interaction inhibitors that alter the docking of NRF2 to KEAP1. b | Electrophiles modify cysteine residues in sensitive proteins. Because KEAP1 is very sensitive to thiol reaction, electrophilic compounds easily induce KEAP1 modification. The window that allows therapeutic KEAP1 modification in the absence of nonspecific thiol modifications within other proteins is represented in the pink area. COOH, carboxy-terminal domain; NH 2 , amino-terminal domain.
Resolution of inflammation. NRF2 is abundant in mono-

Autophagosome
A spherical double-layer membrane structure within the cell. The autophagosome is the key structure in macroautophagy, a type of intracellular degradation process.
NATuRe RevIeWS | DRuG DiSCovERy of NRF2 suppresses production of pro-inflammatory cytokines [51] [52] [53] [54] [55] [56] . In human cells, disruption of KEAP1 protected against sepsis by attenuating the inflammatory response of myeloid leukocytes 57 and macrophages 58 . Of particular interest, a polymorphism in NFE2L2 that is associated with reduced transcriptional activity correlated with increased risk of inflammatory bowel disease (IBD) 59 and chronic gastritis 60 . As indicated below, the robust anti-inflammatory activity of NRF2 has been attributed to at least three independent mechanisms: modulation of redox metabolism; crosstalk with nuclear factor-κB (NF-κB); and direct regulation of pro-inflammatory genes.
Inflammation is associated with increased local and systemic accumulation of pathological levels of ROS that may impair redox signalling 61 . Mitochondrial dysfunction and uncontrolled activation of NADPH oxidase represent the main contributors to heightened ROS production in inflammatory cells, and mitochondrial ROS cause damage and release of mtDNA, thus creating a vicious cycle of events leading to further ROS production and activation of the inflammasome, ultimately resulting in organ debilitation 62 . The redox-regulating activity of NRF2 represents an important break in the vicious cycle that prevents exacerbated inflammation and subsequent tissue damage 63 . NF-κB and NRF2 engage in crosstalk. Several functional NF-κB binding sites have been identified in the NFE2L2 gene promoter 64 . On the other hand, NRF2 inhibits NF-κB transcriptional activity. Treatment of NRF2-deficient mice with lipopolysaccharide (LPS) or TNF increased the expression of the NF-κB transcriptional signature, suggesting an inhibitory role of NRF2 on NF-κB 48 . A possible interpretation of this finding is that the inhibitor of NF-κB (IκB) is highly phosphorylated in NRF2-deficient cells and subject to rapid proteasomal degradation, thereby diminishing inhibition of NF-κB 48 . Additionally, LPS was shown to simultaneously activate both a fast NF-κB-mediated response and a slow NRF2-mediated response, with the initial pro-inflammatory response being driven by NF-κB, which was then subsequently inhibited when NRF2 activity was maximal 65 . Other mechanisms by which the NRF2-KEAP1 axis suppresses NF-κB signalling include competition between NRF2 and p65 for binding to p300 (REf.
66
) and degradation of IκB kinase-β (IKKβ) by KEAP1 (REfS 67, 68 ).
Several macrophage-specific genes contain ARE sequences and are therefore regulated by NRF2. These include MARCO, a receptor required for bacterial phagocytosis, and CD36, a scavenger receptor for oxidized low-density lipoproteins 69, 70 . On the other hand, NRF2 binds to regulatory regions of pro-inflammatory genes encoding IL-6 and IL-1β in an ARE-independent manner and prevents the recruitment of RNA polymerase II to start transcription 52 . Recent studies have provided a connection between macrophage metabolism and the anti-inflammatory responses elicited by NRF2. The mitochondrial metabolite itaconate is produced from the tricarboxylic acid cycle in response to pro-inflammatory stimuli and increases profoundly during macrophage activation 71, 72 . In turn, itaconate alkylates several KEAP1 cysteine sensors, including the critical C151, C273 and C288 residues, thereby activating NRF2 and suppressing transcription of pro-inflammatory cytokines, such as IL-6 and IL-1β 71 . Therefore, itaconate is an endogenous regulator of KEAP1 that acts as an 'off-switch' during the resolution of inflammation. In addition, activation of NRF2 by the cell-permeable itaconate derivative, 4-octylitaconate or SFN, represses the expression of the adaptor molecule stimulator of interferon genes (STING) by decreasing its mRNA stability and consequently suppresses type I interferon (IFN) production 73, 74 .
The NRF2-KEAP1 axis in non-neoplastic disease A wealth of information has been generated in cellular and animal models about the role of NRF2 in providing protection against numerous chronic diseases, with many investigations employing NRF2-knockout mice 75 . Regarding humans, a recent study provided a basis to analyse the contribution of NRF2 in combatting chronic disease using a systems medicine approach and, on the basis of the connectivity of NRF2 with other molecules (NRF2-interactome) along with empirical evidence, established a first map of NRF2-related diseases (NRF2-diseasome) 9 . Compelling evidence for a role of NRF2 in determining the susceptibility of humans to chronic disease is continually being provided by association studies between functional genetic variations of NFE2L2 and disease risk [76] [77] [78] . Moreover, these genetic studies support the hypothesis that drugs mimicking small changes in NRF2 expression reported for some functional variations of NFE2L2 may be of therapeutic value. Below, we briefly describe some milestones in understanding the involvement of NRF2 in human chronic disease and highlight the available genetic evidence.
Autoimmune disease. Oxidative tissue damage and apoptosis lead to the formation of haptens or damaged macromolecules that increase the risk of autoimmune reactions. Because NRF2-regulated enzymes play a critical role in detoxification of many chemicals, it provides a protective mechanism against the environmental susceptibility to autoimmune pathogenesis 79 . Moreover, NRF2 suppresses pro-inflammatory T helper 1 (T H 1) and T H 17 cell responses and activates immunosuppressive regulatory T (T reg ) and T H 2 cells 80 . The relevance of NRF2 in autoimmunity has been extensively studied in experimental autoimmune encephalomyelitis (EAE), which is a mouse model for MS, a chronic inflammatory disease characterized by infiltration of autoreactive immune cells into the central nervous system. In an EAE mouse model, the absence of NRF2 exacerbates disease 81 whereas knockdown of KEAP1 (REf.
52
) or treatment with a range of NRF2 activators, including cyanoenone triterpenoids 82 and SFN
83
, attenuates its severity. In humans, gene expression profiling in patients treated with IFNβ identified NRF2 as a potential mediator of long-term antioxidant response and neuronal preservation 84 . As described below, several biopharmaceutical companies are exploiting the strong evidence that activation of NRF2 is of therapeutic value in MS. Indeed, the only NRF2 activator thus far approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), DMF, is being marketed by Biogen for the treatment of remitting-relapsing MS and psoriasis 85 . A protective role for NRF2 has been suggested in other autoimmune diseases such as systemic lupus erythematous 86, 87 
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Respiratory disease. The lung responds to a variety of environmental toxicants, including smoke, by releasing pro-inflammatory cytokines and chemokines. This primary effect generates a progressive low-grade inflammatory response through the recruitment of circulating monocytes, neutrophils and T cells that release additional inflammatory mediators, ROS and metalloproteinases. The end result is a vicious cycle of damage to lung parenchyma that leads to chronic obstructive pulmonary disease (COPD) or emphysema 93 . NRF2 attenuates the burden to lung parenchyma caused by ROS and inflammation. Cigarette smoke is a major risk factor for the development of COPD and emphysema. Nfe2l2 −/− mice are much more sensitive to the development of cigarette-smoke-induced emphysema than their wild-type counterparts 94 . Furthermore, the development of emphysema following chronic exposure to cigarette smoke was associated with a decline in the expression of cytoprotective genes 95 , whereas the pentacyclic cyanoenone CDDO-imidazolide protected the lungs of Nfe2l2 +/+ , but not Nfe2l2 −/− , mice against cigarette-smoke-induced oxidative stress, alveolar cell apoptosis, alveolar destruction and pulmonary hypertension 96 . Genetic upregulation of NRF2 (by Keap1 deletion in Clara cells, which are abundant in murine upper airways) has a similar protective effect 97 . In humans, the NRF2 transcriptional signature was decreased in alveolar macrophages from patients with smoking-related lung emphysema as compared with patients without emphysema 98 . The human NFE2L2 gene promoter contains a haplotype comprising three single-nucleotide polymorphism (SNP) sequences and one triplet repeat polymorphism that result in modulation of NRF2 expression. COPD patients with low to medium promoter activity were more prone to developing respiratory failure 99 . Pharmacological activation of NRF2 by SFN, or a compound that disrupts the interaction of KEAP1 with NRF2, reversed the impaired bacterial phagocytosis by cultured alveolar macrophages and monocyte-derived macrophages isolated from patients with COPD 70, 100 . However, daily oral administration of SFN (extracted from broccoli sprouts) to COPD patients did not result in consistent changes in NRF2-dependent gene expression or markers of inflammation in alveolar macrophages and bronchial epithelial cells at the doses used 101 , illustrating some of the challenges in translating findings from cell culture studies to humans. Patients with other chronic lung diseases, such as idiopathic (encoding Kelchlike ECH-associated protein 1) and NFE2L2 (encoding transcription factor NF-E2 p45-related factor 2 (NRF2)) are in the 64th and 98th percentiles of abundance of the total transcriptome of the brain. Note that KEAP1 mRNA levels are lower than NFE2L2 mRNA levels, as would be expected because KEAP1 protein has a slower turnover (TAblE 2) . b | Differential distribution of the mRNA for KEAP1 and NFE2L2 in human grey matter from mature brain specimens after removal of meninges and blood clots 309 . Both transcripts are higher in astrocytes and microglia than in neurons. For panels a and b, data were obtained from the Brain-RNAseq database. For details, see REf.
310
. These values are calculated using the function 'density' of the statistical software package R (see Related links). c,d | The mRNA expression of KEAP1 and NFE2L2 in some haematopoietic cells. The size and colour of the dots correlate with the abundance of either KEAP1 (panel c) or NFE2L2 (panel d) mRNAs. Again, mRNA encoding KEAP1 is less abundant than that for NRF2. The relative expression of KEAP1 is low in monocytes, neutrophils and lymphocytes and high in the erythroid lineage whereas NFE2L2 exhibits the opposite trend. For panels c and d, data were obtained from the healthy haematopoiesis samples of the Bloodspot database 311 . DC, dendritic cell; FPKM, fragments per kilobase million; KDE, kernel density estimation; NK , natural killer.
Chronic obstructive pulmonary disease (COPD). Progressive lung disease including emphysema, chronic bronchitis and refractory (non-reversible) asthma.
Emphysema
Progressive lung disease that causes shortness of breath owing to overinflation of the alveoli.
Clara cells
Dome-shaped cells found in the bronchioles of the lungs.
www.nature.com/nrd pulmonary fibrosis, chronic sarcoidosis and hypersensitivity pneumonitis, were found to exhibit increased NRF2 expression and augmented levels of endogenous antioxidants in bronchoalveolar lavage fluids, suggesting an unsuccessful adaptive response to pathological ROS levels 102 .
Gastrointestinal disease. The GI tract is constantly exposed to xenobiotic challenges that can lead to formation of pathological levels of ROS and may provoke IBD 103 . The GI tract is also one of the sites where pharmacological NRF2 activation by dietary agents and their synthetic analogues is highly prominent 23, [104] [105] [106] . In mice, dextran sodium sulfate (DSS)-induced experimental colitis elicits more profound IBD in NRF2-deficient mice than in their wild-type counterparts 107 . In humans, the relevance of NRF2 in adaptation of enterocytes to inflammatory stress was demonstrated in a comprehensive transcriptome study on IBD patients that evidenced its role in attenuation of the stress response of macrophages in the gut 108 . Importantly, a genetic association has been found in a Japanese cohort of patients between a particular SNP in the NFE2L2 gene and the risk of developing ulcerative colitis 109 . The functional haplotype of the three SNPs in the NFE2L2 promoter with slightly reduced expression of NRF2 was associated with development of gastric mucosal inflammation and peptic ulcer in association with Helicobacter pylori infection 60 . The liver represents a first line of defence against food xenobiotics and orally active drugs because a major portion of blood draining the GI tract is directed to the liver via the hepatic portal vein. Early work with Nfe2l2 −/− mice demonstrated the hepatoprotective effect of NRF2 against acetaminophen 110 , as did genetic activation of NRF2 (REf.
111 ). As possibly anticipated, Nfe2l2 −/− mice fed alcohol (4-7 days) are markedly more susceptible to fatty liver aggravated hepatic inflammatory responses and liver failure than are similarly fed wild-type mice, and this is in part likely owing to activation of the SREBP lipogenic transcription factor and a relative inability to detoxify acetaldehyde 112 . The observation that disruption of NRF2 in mice impeded liver regeneration following partial hepatectomy led to the discovery that NRF2 regulates the gene expression of NOTCH1 (REf. 113 ), a mechanism that is also involved in the NRF2-mediated improvement of haematopoietic stem progenitor cell function and myelosuppression following exposure to ionizing radiation 114 . In a mouse model of hereditary haemochromatosis with iron overload (due to mutation of the homeostatic iron regulator gene), knockout of NRF2 increased necro-inflammatory lesions within livers of the knockout mice that led to hepatic fibrosis 115 . Consistent with these observations, patients with primary biliary cholangitis and cirrhosis exhibit reduced NRF2 expression 116 .
Metabolic disease. Metabolic disease, also referred to as metabolic syndrome, is typified by abdominal obesity, hypertension, hypertriglyceridaemia, low levels of high-density lipoprotein and fasting hyperglycaemia. It is closely linked with type 2 diabetes mellitus (T2DM) and associated comorbidities such as vascular dysfunction, cardiovascular disease, glomerulonephritis, nonalcoholic steatohepatitis (NASH; see below) and cognitive impairment. Although T2DM and its comorbidities are characterized by overproduction of superoxide by mitochondria 117 , NRF2-null mice do not spontaneously develop diabetes. Indeed, the knockout mice exhibit increased insulin sensitivity, which has been attributed to ROS-mediated inhibition of protein tyrosine kinase phosphatase 1B that antagonizes insulin signalling 118 . By contrast, genetic activation of NRF2 by knockout or knockdown of KEAP1 in mice on a db/db background, or pharmacological activation of NRF2 in db/db mice, suppresses the onset of T2DM 119 . Therefore, it seems likely that when pancreatic β-cells are metabolically challenged to synthesize insulin in response to hyperglycaemia, the resulting ROS burden may cause oxidative damage that impairs the response, leading to T2DM 120, 121 . If this conclusion is correct, it is probable that improved pancreatic function contributes significantly to the improved glucose disposal observed following pharmacological activation of NRF2 by TBE-31 or SFN in mice with diet-induced T2DM 122, 123 and in the reduction of fasting blood glucose and glycated haemoglobin (HbA1c) by SFN-rich broccoli sprout extracts in obese patients with dysregulated T2DM 123 . In addition to imparting increased resilience to oxidative stress on pancreatic β-cells, NRF2 activation may contribute to improved whole-body glucose homeostasis by suppressing glycogen breakdown in skeletal muscle through increasing expression of glycogen branching enzyme and phosphorylase b kinase-α 119 . In mouse models of diabetic nephropathy, pharmacological activation of NRF2 by SFN or cinnamic aldehyde has been shown to suppress oxidative stress, transforming growth factor-β1 signalling and fibrosis 124 . It seems likely that NRF2 plays a key role in insulin resistance as suggested by the fact that its expression is low in the monocytes of patients with diabetes 125 . Compelling evidence comes from genetic association studies indicating that some NFE2L2 polymorphisms that result in low NRF2 expression lead to pathological ROS levels and increased risk of T2DM [126] [127] [128] . Regarding complications, a failure of antioxidant protection due to demethylation of the CpG islands in the KEAP1 promoter has been linked to diabetic cataracts 129 . NRF2 may also be protective against the development of NASH. In a mouse model of NASH that involves administration of a diet deficient in methionine and choline, NRF2-null mice succumbed to the disease much more rapidly than did wild-type mice 130, 131 . In a more physiological model of NASH, NRF2-deficient mice fed a high-fat diet also developed exacerbated hepatic steatosis and inflammation, suggesting the need for NRF2 to suppress the onset of these symptoms 118, 132 . Furthermore, pharmacological activation of NRF2 by the tricyclic cyanoenone TBE-31 in wild-type, but not NRF2-knockout, mice, which had been rendered obese and insulin resistant by chronic consumption of a high-fat and highfructose diet, reversed insulin resistance, suppressed hepatic steatosis and ameliorated both NASH and liver fibrosis 122 . Pharmacological activation of NRF2 by TBE-31 antagonizes SREBP1c and ChREBP and expression of their lipid-biosynthetic target genes, which likely involves activation of AMPK 122, 133 . Moreover, in mouse liver, genetic activation of NRF2 antagonizes expression of the gluconeogenic enzymes PEPCK and G6PC, which may also involve AMPK 133 . In liver biopsy samples of NASH patients, pathological ROS levels were found together with an increased NRF2 gene signature, suggesting an attempt to reduce the oxidant and inflammatory burden 134 . Cardiovascular disease. An imbalance between the production and disposal of ROS resulting in excessive formation of damaging oxidative species has been postulated to play a role in a number of cardiovascular diseases, such as hypertension, atherosclerosis, diabetic vascular disease, myocardial ischaemia-reperfusion injury and heart failure 135 . In addition, low-grade, persistent inflammation within the vascular wall is characteristic of the atherogenic process and development of vulnerable atherosclerotic plaques that are prone to rupture, subsequently leading to thrombosis and end-organ ischaemia. Given that NRF2 is the key regulator of antioxidant defence and also has direct antiinflammatory properties, it is logical to assume that NRF2 would protect against ROS-related cardiovascular disease. Indeed, NRF2-activating agents, including fumarate and hydrogen sulfide, have shown protective effects in many animal models of cardiovascular disease, such as cardiac ischaemia-reperfusion injury 136, 137 and heart failure 138, 139 . The role of NRF2 in atherosclerosis in mouse models of hypercholesterolaemia is less straightforward: the loss of NRF2 in bone-marrow-derived cells aggravates atherosclerosis 140, 141 , whereas global deficiency of NRF2 alleviates atherosclerosis assessed by the extent of lesion development [142] [143] [144] [145] yet increases plaque inflammation and vulnerability 145 . Nevertheless, several NRF2-activating agents have been shown to be atheroprotective in a variety of animal models of atherosclerosis [146] [147] [148] . Cardiac diseases caused by mutations in contractile, cytoskeletal proteins and molecular chaperones can account for about 30% of inheritable cardiomyopathies 149 . In some of these settings, reductive rather than oxidative stress, coupled with protein aggregation, is associated with the cardiomyopathies. Systemic inflammation and pathological ROS formation in patients on haemodialysis are associated with downregulation of NRF2 (REf.
150
), and a polymorphism located in the NFE2L2 promoter has been associated with increased mortality in these patients 151 . Disruption of the NRF2 signalling axis prevents reductive stress and delays proteotoxic cardiac disease in mice overexpressing human CRYAB (α-crystalline B chain), a molecular chaperone, in the heart 152 . Thus, as highlighted throughout this Review, the context for targeting NRF2 is very important -more may not always be better.
Neurodegenerative disease. In various forms of neurodegenerative disease, the connection between NRF2 and proteostasis is particularly pertinent because these diseases are characterized by abnormal protein aggregation 43 . Compelling evidence for a protective role of NRF2 in proteinopathy has been provided in Alzheimer disease (AD) models of amyloidopathy , two essential mechanisms for clearance of APP, tau and α-synuclein. Upregulation of NRF2 protected neurons against the toxicity of mutant α-synuclein and leucinerich repeat kinase 2 (LRRK2) 162 , which also leads to neurodegeneration associated with accumulation of misfolded proteins 163 . Curiously, whereas NRF2 activation increased the degradation of α-synuclein, misfolded diffuse LRRK2 was sequestered into inclusion bodies.
The role of NRF2 in astrocytes and microglia is expected to be especially relevant as they show the highest expression levels in the brain (fig. 2b) . Using transgenic mice with an ARE-driven alkaline phosphatase reporter gene, it was found that astrocytes are highly responsive to NRF2 activation in several models of neurodegeneration 164 , pointing to the relevance of NRF2 in the nurturing effect of astrocytes by providing metabolic and GSH precursors to endangered neurons 46,165 . Microglia, as the immune response cells of the brain, are also crucial in NRF2 mediated responses 166, 167 . In the murine model of PD based on intoxication with the parkinsonian toxin methyl-4-phenyl-1,2,3,6-tetrahydropyridine, it was reported that NRF2 modulates microglial dynamics and thereby reduces production of COX2, NOS2, IL-6 and TNF and increases the levels of several anti-inflammatory markers 55, 168 . The activation of microglia by tau-injured neurons appears to be related, at least in part, to the crosstalk through the chemokine fractalkine. Both in mice and in humans, tau-injured neurons release fractalkine, which in neighbouring microglia inhibits GSK3 and leads to increases in NRF2 protein.
In turn, NRF2 reduces the release of TNF and IL-6 and participates in the reprogramming of microglia towards a wound-healing response 161 . Several NRF2-target genes, including HMOX1, NQO1, GCLM and SQSTM1, are upregulated in AD and PD brains 159,169-171 . The relevance of this upregulation is demonstrated by genetic analyses of the association between disease risk and the functional haplotype made of three SNPs in the NFE2L2 promoter. In amyotrophic lateral sclerosis (ALS), a protective haplotype allele was associated with a 4-year delay in disease onset 172 , but another study did not find a clear association 173 . In AD, another haplotype variant was associated with a 2-year earlier onset of disease 76 . More detailed evidence has been reported for PD. Initially, a protective haplotype was associated with delayed onset of disease in a Swedish cohort and reduced risk in a Polish cohort of patients with PD 77 . Afterwards, these findings were replicated in four independent European case-control studies 174 , but not in a Taiwanese population 175 , suggesting differences in ethnicities and/or environmental factors.
Pharmacological activation of NRF2 also holds promise for the treatment of Huntington disease (HD) and Friedreich ataxia (FRDA), in which oxidative stress and inflammation are important drivers of pathology.
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Studies in mice, model organisms and cultured cells from patients with HD and FRDA have reported impaired NRF2 signalling 53,176-178 and the beneficial effects of pharmacological NRF2 activators. Thus, activation of NRF2 by triazole derivatives suppressed the release of pro-inflammatory cytokines in primary mouse HD microglia and astrocytes and in cultured monocytes from patients with HD 53 and was neuroprotective in ex vivo HD rat corticostriatal brain slices and an HD Drosophila model 179 . In mouse models of HD, DMF and the triterpenoids CDDO-ethyl amide and CDDOtrifluoroethyl amide improved the brain pathology and behaviour of the animals 180, 181 . Treatment with SFN and the cyclic cyanoenones TBE-31 or RTA-408 led to improved mitochondrial function and protection against oxidative stress in fibroblasts and cerebellar granule neurons from FRDA mouse models, and in fibroblasts from patients with FRDA 182, 183 . Altogether, the available evidence suggests that a modest activation of NRF2 is neuroprotective in the brain.
The NRF2-KEAP1 axis and cancer NRF2 has been reported to exert both anti-tumorigenic and pro-tumorigenic actions. Here, we provide a brief summary of the current understanding of the role of NRF2 in cancer and refer the reader to a recent comprehensive review discussing NRF2 in the context of the hallmarks of cancer 12 .
In non-malignant cells, NRF2 activation affords resistance to oxidant-induced genetic damage and chemical and physical carcinogens owing to enhanced defences that include antioxidant 184 and radioprotective 114 activities as well as accelerated biotransformation and clearance of DNA-damaging agents 185 . Moreover, activation of the NRF2 transcriptional response appears to maintain ROS levels below those necessary for signalling to proteins critical for tumorigenesis, such as phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), mitogen-activated kinases, hypoxia inducible factor 1 and NF-κB 186 . By contrast, in the early stages of tumour development, cancer cells with constitutive activation of NRF2 are selected as a means of enabling adaptation to a hostile microenvironment, chemotherapy, radiotherapy or high endogenous ROS levels. Additionally, in rapidly proliferating cells, NRF2 supports intermediary metabolism by enhancing the biosynthesis of nucleotides 26 and amino acids 187 but also generates metabolic imbalance and dependence on glutaminolysis, which could be therapeutically exploited 188, 189 . Somatic loss-of-function mutations in KEAP1 or gain-of-function mutations in NFE2L2 are common in non-small-cell lung cancer and some other cancers in which environmental factors are important aetiological components 190 . A comprehensive catalogue of NRF2 mutations in The Cancer Genome Atlas (TCGA) database identified 226 unique NRF2-mutant tumours within 10,364 cases, with gain-of-function NRF2 mutations occurring in 21 out of 33 tumour types 191 . The frequent occurrence of such mutations suggests a potential benefit of NRF2 inhibitors in cancer treatment, triggering a search for such agents (bOx 1). These NRF2 inhibitors represent a completely open field for pharmacology that at this time is at the level of proof-of-concept research. Alternative approaches for NRF2 suppression include targeting proteins that confer dependence on NRF2 and/or are selectively expressed in KEAP1-mutant cancer cells. Examples include inhibitors of glutaminase 188, 189 and NR0B1, an atypical orphan nuclear receptor that participates in a multimeric protein complex to regulate transcription in KEAP1-mutant cells 192 . However, it should be noted that no evidence exists to date that either KEAP1 or NFE2L2 mutation alone can instigate malignant transformation, but co-occurrence with oncogenic drivers seems necessary, with PI3K pathway alterations having the strongest association 193 . Most tellingly, the hypomorphic 'Keap1-knockdown' mouse in which NRF2 is globally upregulated does not spontaneously develop tumours 194, 195 , whereas the simultaneous deletion of Keap1 and Pten in the murine lung promotes adenocarcinoma formation 195 . Importantly, the resulting tumours are characterized by an immunosuppressive microenvironment, which can be therapeutically exploited by use of immune checkpoint inhibitors 195 . G12D ) activation of NRF2 signalling in rodents can increase tumour development 196 ,whereas genetic knockdown of Keap1 (also leading to activation of NRF2 signalling) strongly blunts NOTCH1-driven tumorigenesis 197 as well as ultraviolet-radiation-mediated cutaneous carcinogenesis 51, 198 . Notably, in the latter model, the protective effect of KEAP1 knockdown against initiation of cutaneous carcinogenesis is abrogated by the simultaneous loss of NRF2 (REf. 199 ). This dichotomous role of NRF2 is supported by extensive experimental evidence in which its activation enhances antitumour immunity to prevent lung carcinogenesis, but only after tumour initiation accelerates malignant growth 200 . In addition, Nfe2l2-knockout mice submitted to chemically induced carcinogenesis exhibit an increased number of tumours (enhanced initiation) but of much smaller size (impaired progression) compared with wild-type littermates 201 . Hence, low NRF2 activity facilitates initiation of carcinogenesis, whereas persistent constitutively high NRF2 activity can drive cancer progression and resistance to therapy 202 .
It is clear that the context within which NRF2 is genetically activated is important in terms of tumorigenesis, as oncogene (Kras
NRF2 modulators in clinical development
Fumaric acid esters. Fumaric acid esters represent a group of NRF2 activators upon which industry is focusing much effort. The most clinically successful example is DMF (compound 1, fig. 3a) , which was approved in 1994 for the treatment of psoriasis and, on the basis of its efficacy in the EAE mouse model of MS 203 , was repurposed in 2014 by Biogen (Tecfidera) for the treatment of relapsing-remitting MS. Early studies in rodents preceding the discovery of NRF2 had reported that DMF is a robust inducer of the NRF2-transcriptional targets GST and NQO1 (REf.
204
), and it was later shown that the DMF metabolite monomethyl fumarate (MMF; compound 2, fig. 3a ) reacts with C151 in KEAP1, thereby activating NRF2 (REf.
203
). Safety has been a priority since the discovery of the inducer activity of DMF, and it was noted that NATuRe RevIeWS | DRuG DiSCovERy the concentrations of DMF required to obtain significant enzyme inductions were well tolerated by rodents 204 . DMF exhibited a favourable safety and tolerability profile in two phase III trials 205, 206 , and since its commercialization it has become one of the most successful new medicines in recent years. However, a drawback of Tecfidera is the occurrence of mild to moderate abdominal pain, flushing, diarrhoea and nausea. Although these adverse effects can be managed, a more serious symptom is the occurrence of leukopenia in patients with low leukocyte counts at the beginning of treatment. In fact, animals treated with DMF had much lower levels of granulocytes in their nervous system than those that did not receive the drug 207 . This effect is not related to NRF2 but is most likely due to activation of the hydroxycarboxylic acid receptor, because mice lacking this protein had high levels of granulocytes regardless of whether they were treated with DMF 207 . These observations highlight the importance of carefully selecting the inclusion criteria for treatment.
As mentioned above, DMF is metabolized in vivo to MMF, which inactivates KEAP1 through adduct formation at C151 (REf. 203 ). Because of this metabolic conversion, several biopharmaceutical companies are now developing compounds with slow and sustained release of MMF that would show improved bioavailability and fewer side effects than DMF (TAblE 1) . Alkermes (acquired by Biogen) has developed diroximel fumarate (BIIB098 (previously ALK8700), compound 3; fig. 3a) , an MMF prodrug with reduced GI side effects that is now in a phase III clinical trial for MS (NCT03093324). XenoPort (acquired by Arbor Pharmaceuticals) has developed tepilamide fumarate, an MMF prodrug (XP23829, compound 4, fig. 3a) . Compared with DMF, XP23829 has higher solubility and permeability, greater absorption following oral administration, improved efficacy and reduced GI side effects in preclinical models and is now in a phase II clinical trial for plaque psoriasis (NCT02173301). Catabasis Pharmaceuticals is developing another chemically linked conjugate of MMF and docosahexaenoic acid (CAT4001), with potential for enhanced cell targeting, efficacy, improved safety and tolerability compared with the effect of separate bioactive molecules. Specific enzymes release the two components inside the cell, where they simultaneously modulate multiple biological targets, including NRF2 and NF-κB in cells and animal models, and show promise for the treatment of neurodegenerative diseases, such as FRDA and ALS. A similar technology is being developed by V ClinBio in their conjugates of MMF and eicosapentaenoic acid (VCB101, compound 5, fig. 3a and VCB102) for the treatment of MS and psoriasis (TAblE 1) .
Sulforaphane.
A widely used naturally occurring electrophilic activator of NRF2 is SFN (compound 6, fig. 3a ). This compound was initially isolated by Paul Talalay and Yuesheng Zhang as the principal inducer of the NRF2-target enzyme NQO1 from extracts of Brassicaceae plants 208 and interacts with C151 of KEAP1
(REfS 14,209 ). Notably, SFN goes through the blood-brain
Box 1 | Emergence of NRF2 inhibitors for cancer treatment
Somatic mutations in the Kelch-like eCH-associated protein 1 (KeAP1)-transcription factor NF-e2 p45-related factor 2 (NRF2) axis have been found in several tumour types 193 , suggesting a potential benefit of NRF2 inhibitors in cancer treatment. Following ligand-mediated receptor activation and binding to the glucocorticoid response element, agonists of the glucocorticoid receptor, such as dexamethasone, inhibit the transcriptional activity of NRF2, at least on the GSTA2 gene 291 . Agonists of the nuclear receptors retinoic acid receptor-α (RARα) and retinoid X receptor-α (RXRα), including all-trans-retinoic acid, also inhibit the transcriptional activity of NRF2 in an antioxidant response element (ARe)-reporter cell line and in the small intestine of mice fed a vitamin-A-deficient diet 292, 293 . It is likely that these mechanisms of regulation through nuclear receptors are not specific for NRF2, although RXRα has been reported to interact directly with NRF2 (REf.
293
).
Among pharmacological agents, brusatol, a quassinoid extracted from Brucea javanica, attracted initial attention as it reduced the expression of an ARe-luciferase reporter and sensitized a broad spectrum of cancer cells to cisplatin in culture and in xenografts 294 . However, it is now recognized that brusatol is a general inhibitor of protein synthesis, thus leading to the preferential inhibition of short-lived proteins, including but not limited to NRF2 (REfS 295, 296 ). A similar concern was raised after the identification of the febrifugine derivative halofuginone in a high-throughput inhibitor screen in chemo-resistant and radio-resistant cancer cells 297 . Halofuginone induced a cellular amino acid starvation response that repressed global protein synthesis and rapidly depleted NRF2 and other proteins. The flavonoid luteolin was reported to accelerate the turnover of NRF2 mRNA and thus elicit a strong reduction of NRF2 protein and mRNA levels and sensitize cells to anticancer drugs 298 . However, subsequent studies provided conflicting results as they report that luteolin is an NRF2 activator 299, 300 . Another flavonoid, wogonin, has also yielded conflicting results 301, 302 . The coffee alkaloid trigonelline inhibited the nuclear accumulation of NRF2 protein 303 and reduced NRF2-dependent proteasome activity in several pancreatic cancer cell lines 304 . Nevertheless, these effects need to be addressed in a wider range of cell types before being taken to preclinical studies.
Targeting the interaction between NRF2 and small musculoaponeurotic fibrosarcoma oncogene homologue (smAF) proteins might be a promising strategy. Thus, a quantitative high-throughput screen identified a thiazole-indoline compound as an NRF2 inhibitor, and medicinal chemistry optimization led to compound ml385, which was found to bind the carboxy-terminal domain of NRF2 and interfere with the formation of the NRF2-smAF protein heterodimer that is required for activation of ARe-driven gene expression 305 . Further work is needed to determine whether ml385 is selective for NRF2-smAF interaction or also affects other basic-region leucine zipper transcription factors. moreover, this compound elicits a reduction of NRF2 protein levels; therefore, additional mechanisms of NRF2 regulation may operate. other NRF2 inhibitors with unknown mechanism of action include malabricone A 306 , ochratoxin A 307 and Aem1 (REf.
308
However, these compounds also do not appear to be specific for NRF2 inhibition.
www.nature.com/nrd barrier 55 and has protective effects in numerous preclinical models of neurological conditions 210 . In a doubleblind placebo-controlled clinical trial in young men with autism spectrum disorder, orally administered capsules of SFN-rich broccoli sprout extracts have elicited significant improvement in behavioural measures as assessed by the Aberrant Behaviour Checklist and Social Responsiveness Scale; the total scores on these scales reversed towards pretreatment levels upon cessation of treatment 211 . Three-day-old broccoli sprouts are rich in glucoraphanin, a precursor molecule that is hydrolysed by the plant enzyme myrosinase to release SFN and glucose 212 . A similar β-thioglucosidase enzyme is present in the gut microbiota; therefore, the actual levels of released ; the protein is shown in a surface representation and the subpockets 245 of the protein-protein interface are coloured as follows: P1 subpocket, red (residues 415, 461, 462, 478, 483 and 508); P2, blue (363, 380, 381 and 414); P3, yellow (364, 509, 556, 571, 602 and 603); P4, green (334, 572 and 577); and P5, cyan (525, 530 and 555). Subpocket occupancy for ligands 13-16 (using the same colour scheme) was determined from crystal structures 4XMB (by analogy to the bis-amide analogue), 5FNU, 4L7B and 3VNH, respectively. IVR , intervening region.
SFN are highly dependent on dietary habits and microbiome composition, are affected by antibiotic treatments 213 and display circadian rhythmicity 214 . Nevertheless, either as sprout extract or highly purified SFN, more than 500 subjects have received over 25,000 doses, demonstrating a high safety profile. There are currently over 20 ongoing clinical trials.
Considering issues related to intellectual property surrounding a natural compound, the fact that SFN is unstable at room temperature, and the need to accurately control dosing, Evgen Pharma has developed a pharmaceutical form of SFN, SFX-01 (compound 7, fig. 3a ). SFX-01 is chemically synthesized SFN encapsulated in cyclodextrin to create a stable, solid-form pill or capsule with excellent bioavailability. SFX-01 is now being studied in clinical trials of subarachnoid haemorrhage (NCT02614742) and metastatic breast cancer (NCT02970682) (TAblE 1) . Evgen also has a series of novel SFN-based analogues that are in preclinical evaluation. In addition, a number of nutraceutical companies are producing preparations that contain NRF2 inducers, including SFN, with various degrees of standardization. One example is Prostaphane, from the Nutrinov Laboratory, which is a stabilized free SFN, extracted from broccoli seeds, with demonstrated benefits in managing biochemical recurrences after radical prostatectomy in a placebo-controlled clinical trial of prostate cancer 215 . The bioavailability and potency of both SFX-01 and Prostaphane are equivalent to those of the much less stable SFN 216 . Another example is the encapsulated dietary supplement Avmacol (Nutramax Laboratories), which contains glucoraphanin from finely milled broccoli seeds together with freeze-dried broccoli sprout powder to provide myrosinase. This supplement is currently in use in clinical trials to modulate disease symptoms and/or biomarkers related to autism spectrum disorder, schizophrenia and environmental pollution 217 .
Cyanoenone triterpenoids. Accumulating evidence suggests that fumaric acid esters, SFN and other small electrophiles that bind covalently to KEAP1 may benefit from a larger scaffold structure to confer better selectivity (and likely potency) and more controllable pharmacokinetic and/or pharmacodynamic properties. The development of pentacyclic Michael acceptor-bearing cyanoenone triterpenoids may fulfil these requirements. Initially developed by Michael Sporn, Gordon Gribble and Tadashi Honda from the natural product oleanolic acid 218, 219 , these pentacyclic triterpenoids are the most potent electrophilic NRF2 activators known to date 220 , are sensed by C151 in KEAP1 and are now under clinical development by Reata Pharmaceuticals and Kyowa Hakko Kirin.
Two clinically advanced compounds, bardoxolone methyl (BARD; compound 8, fig. 3a ) and omaveloxolone (compound 9), normalize metabolism, increase mitochondrial energy production, boost cellular antioxidant capacity and lower ROS levels 221 (TAblE 1) . In preclinical studies, BARD or analogues have been shown to improve kidney function by reducing inflammation, fibrosis and oxidative stress and increasing the filtration surface area in the glomerulus 222, 223 . With a modification of the selection criteria to exclude patients with signs of incipient heart failure (elevated B-type natriuretic peptide), BARD is now being tested in clinical trials for several rare conditions that are associated with chronic kidney disease (CKD), most of which have no approved treatments, including Alport syndrome (NCT03019185), autosomal dominant polycystic kidney disease, immunoglobulin A (IgA) nephropathy, type 1 diabetes and focal segmental glomerulosclerosis (NCT03366337), in which pro-inflammatory and pro-fibrotic processes contribute to glomerulosclerosis and impaired kidney function 224 . BARD treatment has the potential to delay or prevent the decline in glomerular filtration rate that results in the need for dialysis or transplant in patients with Alport syndrome and other rare forms of CKD. Thus, in a phase II clinical trial in patients with T2DM and CKD (NCT02316821), BARD treatment led to statistically significant increases in directly measured glomerular filtration rate and, upon exclusion of patients at risk of fluid retention, was well tolerated. On the basis of these results, Kyowa Hakko Kirin has initiated a phase III clinical trial (NCT03550443), with the support of the Japanese SAKIGAKE Designation system, in patients with diabetes with stage G3 or G4 CKD.
In addition, BARD is being studied in patients with pulmonary arterial hypertension (PAH) (NCT03068130) and PAH due to connective tissue disease (CTD-PAH) (NCT02657356), which is a serious and progressive disease that leads to heart failure and death. The difference between CTD-PAH and idiopathic aetiologies is largely attributed to the complex interplay between the inflammation, autoimmunity and systemic vasculopathy that contribute to the pathogenesis of connective tissue disease. Patients with CTD-PAH have increased inflammatory processes owing to upregulation of NF-κB 225 , are less responsive to existing vasodilator therapies than patients with idiopathic PAH and have a worse prognosis 226 . BARD was tested in patients with CTD-PAH in a phase II study and is currently being tested in a phase III study. Omaveloxolone is currently being tested in a registrational phase II clinical trial for patients with FRDA (NCT02255435), a genetic neuromuscular disorder in which NRF2 is downregulated [176] [177] [178] . Of note, there are no currently approved therapies for the treatment of FRDA 227 (TAblE 1) .
Nitro fatty acids. Nitrated derivatives of fatty acids (NO 2 -FAs) are endogenous signalling mediators with anti-inflammatory and anti-fibrotic activities in preclinical animal models of metabolic and inflammatory disease 228 . The nitroalkene group confers electrophilicity to their β-carbon, promoting the rapid formation of reversible NO 2 -FA Michael adducts with nucleophiles, such as cysteines, a modification termed nitroalkylation 229, 230 . It has been shown that nitro-oleic acid (NO 2 -OA; 9-nitrooctadec-9-enoic acid) reacts with cysteines in KEAP1, including C273 and C288, thereby activating NRF2 (REfS 231, 232 ). The reversibility of this reaction 229, 230, 233 prevents the possibility for accumulation of stable NO 2 -FA thiol adducts, which could lead to cytotoxicity. Indeed, phase I safety evaluation has demonstrated that the lead compound, CXA10 (10-NO 2 -OA; 10-nitro-octadec-9-enoic acid, a specific regio-isomer of NO 2 -OA) Alport syndrome genetic disorder of the glomerular basement membrane, part of the glomerular filtration unit, characterized by kidney disease, hearing loss and eye abnormalities.
www.nature.com/nrd (compound 10, fig. 3a) is safe in humans at pharmacologically active doses 234 . CXA10 is currently being developed by Complexa as a treatment for focal segmental glomerulosclerosis and PAH 234 (TAblE 1) . The synthesis and biological evaluation of nitroalkenes derived from α-tocopherol were also recently reported 235 .
Hydroxylamine.
A special challenge is to deliver NRF2 activators that can pass the blood-brain barrier. The route of administration (injection, oral or topical) is also crucial for specific diseases. Othera Pharmaceuticals (now acquired by Colby Pharmaceutical) is developing a di-substituted hydroxylamine with antioxidant properties (OT551) for topical use that inhibits oxidative stress and disease-associated inflammation by targeting KEAP1 (compound 11, fig. 3a) . In preclinical studies, an ophthalmic solution of this compound protected the retinal pigment epithelium and photoreceptors from oxidative damage and inflammation, and a phase II trial on age-related macular degeneration has demonstrated efficacy in preventing the progression of vision loss (NCT00485394) (TAblE 1).
TFM735.
A high-throughput screening reporter strategy assessing the stability of a chimeric protein comprising the NRF2 amino-terminal domain fused to LacZ (NRF2d-LacZ) 236 identified TFM735 as a lead compound (compound 12, fig. 3a ). TFM735 activates NRF2 in a C151-dependent manner and inhibits the synthesis of IL-6 and IL-17 from stimulated human peripheral blood mononuclear cells and the progression of EAE in mice 237 . This compound is currently in preclinical development by Mochida Pharmaceuticals for the treatment of MS (TAblE 1) .
NRF2-KEAP1 protein-protein interaction inhibitors.
Recent attention has focused on the development of nonelectrophilic non-covalent compounds that interfere with the direct PPI between KEAP1 and NRF2 (REf.
238
), or the PPI between KEAP1 and CUL3 (REf. 239 ). By interfering directly with the interaction between KEAP1 and NRF2 or CUL3, the compounds do not require a covalent binding component for their mode of action. There are potential advantages to this approach, including the scope to explore new chemotypes of NRF2 inducer, different pharmacodynamics due to a different mode of interaction with KEAP1 and different off-target effect profiles due to a cysteine-independent binding mechanism. There is evidence that electrophilic and non-electrophilic (PPI) KEAP1 inhibitors differ in their spectrum of biological effects, an example being the ability of non-electrophiles to induce mitophagy in contrast to electrophiles such as SFN and DMF; this points towards potential differences in pharmacological activity and therapeutic utility between the two compound classes 240 . The design of PPI inhibitors has been guided by the availability of the crystal structure of the Kelch domain of KEAP1 (REfS [241] [242] [243] ) (fig. 3b) . Several types of PPI inhibitor have been reported; the major chemical classes developed with input from the pharmaceutical industry are shown in fig. 3b . The naphthalene bis-sulfonamide compounds originated from a high-throughput screening campaign at Biogen 244 and subsequently elaborated by Jiang et al. 245 at China Pharmaceutical University to provide compound 13 (CPUY192018) and analogues. This bis-carboxylic acid compound is a high-affinity ligand for KEAP1, which induced the expression of ARE-dependent genes at low-micromolar concentrations. Astex and GlaxoSmithKline also identified sulfonamide-containing lead compounds from an X-ray crystallography fragment-based screening programme. The lead compounds in this case are exemplified by compound 14, a low-nanomolar inhibitor of the KEAP1-NRF2 PPI that increased the expression of the NRF2-target gene NQO1 in treated epithelial cells derived from patients with COPD. The compound was capable of reducing lung inflammation in rats after intravenous administration and effectively suppressed ozoneinduced accumulation of leukocytes in bronchoalveolar fluid and restored GSH concentrations 246 . Compounds from this series have shown efficacy in several animal models of oxidative stress that simulate features of pulmonary disease and are currently being developed for clinical evaluation. Two further classes of mono-acidic PPI inhibitors have been developed that are not sulfonamides. The first class, developed at Rutgers by Hu et al. 247 and elaborated by Evotec and UCB Pharma 248 , included the tetrahydroisoquinolines (for example, compound 15), which were low-micromolar inhibitors of the KEAP1-NRF2 PPI. The second class was developed by Toray Industries and RIKEN and incorporated an oxadiazole motif; compound 16 is an inhibitor of the PPI with binding activity in the micromolar range 249 . The highlighted compounds or their analogues have been co-crystallized with the KEAP1 Kelch domain; fig. 3b illustrates the occupancy of the binding site subpockets that compounds 13-16 achieve and provide insights into how these ligands may be refined in the future.
New PPI inhibitors are also being developed by C4X Discovery using a combination of computational chemistry, ligand NMR spectroscopy and protein crystallography approaches and by Keapstone using a structure-based drug design approach. Academic groups are also contributing to the pool of non-electrophilic NRF2 inducers 250, 251 . A major challenge remains in making PPI inhibitors that possess suitable drug metabolism and pharmacokinetic properties for use in both peripheral and central nervous system applications, the latter being an area in which NRF2 activators with a strong safety profile are required for chronic administration for conditions such as AD and PD. At this time, the potential advantage of improved target selectivity of the nonelectrophilic PPI inhibitors is offset by the fairly high molecular mass of the current compounds, a requirement for blocking the large KEAP1-NRF2 interface, and the need for polar functional groups to confer tight KEAP1-binding affinity. Thus, many of the prototype compounds that were identified by in vitro studies at present exhibit poor absorption, distribution, metabolism and excretion properties. For instance, the naphthalene bis-sulfonamide (compound 13) protects against DSS-induced colitis in mice, activates NQO1 expression in cultured NCM460 cells in the low-micromolar range and binds KEAP1 in vitro with a K d in the nanomolar range, demonstrating the offset between protein binding and biological activities 252 . The majority of the in vivo evaluations of PPI inhibitors have focused on peripheral inflammatory conditions. For example, the compound NK-252 (an analogue of compound 16) was identified by Toray Industries as a fairly weak KEAP1 inhibitor but had a protective effect against H 2 O 2 -induced cytotoxicity and reduced the fibrosis score in rats fed with a choline-deficient l-amino-acid-defined diet 253 , a model system for NASH.
Targeting NRF2 with KEAP1-independent drugs. Increasing evidence indicates that NRF2 exhibits multiple layers of regulation in addition to that exerted by KEAP1, such as transcriptional 196 , epigenetic 254, 255 , covalent protein modification 256, 257 , proteasome degradation in a KEAP1-independent manner [258] [259] [260] [261] and regulation of NRF2-dimerizing partners that target binding to ARE sequences 262, 263 . At the level of pharmacological development, a KEAP1-independent mechanism of ARE-mediated gene regulation involves modulation of the transcriptional repressor BACH1 (broad complex, tramtrack and bric à brac and cap'n' collar homology 1), which inhibits the transactivation of a subset of NRF2-regulated genes and more specifically HMOX1 (REf.
).
vTv Therapeutics is now analysing whether this subset is sufficient to elicit therapeutic benefits. They have developed a novel class of non-electrophilic small molecules that inhibit BACH1 binding to some ARE-driven genes independently of KEAP1 (REf.
264
Challenges and considerations
Pharmacodynamic assessment. Considering that NRF2 has a very short half-life, even after drug-induced stabilization, the most appropriate dosing regimen for a therapeutic benefit needs to be inferred by indirect indicators of its activation in the diseased organs. One possibility is to analyse drug distribution and NRF2 gene expression signatures in accessible cells or tissues (such as peripheral blood mononuclear cells, nasal lavage fluid cells, exfoliated bladder cells, buccal cells and skin) with the hope that the transcriptomic signature of NRF2 in these cells reflects local engagement in other tissues (such as the lung, liver and brain) [265] [266] [267] . In the case of communities unavoidably exposed to harmful environmental chemicals, the urinary levels of their corresponding metabolites have been used as biomarkers of pharmacodynamic action mediated through NRF2 (REfS 268, 269 ).
Activation of the NRF2 pathway is characterized by a differential gene expression that is dependent on time, tissue, dose, onset and duration. TAblE 2 shows the half-lives of a representative subset of NRF2-regulated gene products. As many of these proteins have a fairly long half-life, their biochemical activities are expected to last much longer than the time interval over which NRF2 is stabilized or the presence of its pharmacological activator, the latter of which is often cleared within several hours. As such, the pharmacodynamics of NRF2-activating molecules are observed over much longer periods of time than the levels of NRF2 and do not correspond to the plasma drug concentrations. Thus, the NRF2 activator TBE-31, a tricyclic cyanoenone closely related to the triterpenoids described above, has a halflife of 10 h in murine skin and plasma 51, 270 , whereas NRF2-dependent induction of NQO1 protein is still evident in the skin of the animals 3 days after the last dose of topically applied drug 51 . Because NRF2 activators lead to the "stimulation of the production or inhibition of factors which control the measured effect", an "indirect pharmacodynamic response" model 271, 272 may be a more logical approach for testing the NRF2 activator pharmacodynamics towards clinical applications.
The concentration and distribution of NRF2-activating drugs in the relevant tissue, as well as their solubility, cell permeability, metabolic stability and protein binding, will also play a major role in the extent of NRF2 activation, ultimately leading to the desired long-lasting pharmacodynamic effects. Therefore, optimization of clinically meaningful drug exposure requires an analysis of dose-dependent gene regulation by a putative NRF2 activator. Furthermore, NRF2-target engagement studies must consider patient age and performance status, as the ability of drugs to activate NRF2 or promote an 'adaptive response' appears to be reduced in older and less healthy subjects. This observation was recently seen in a clinical trial of DMF in patients with relapsing-remitting MS, where it was found that the degree of induction of the NRF2 transcriptional target NQO1 negatively correlated with patient age, and that patients with higher NQO1 protein levels at 4-6 weeks after the start of therapy were more likely to show no evidence of disease activity during the following year 267 .
Drug selectivity. The identification of highly reactive cysteines in KEAP1 was crucial for the understanding of the mechanism by which electrophilic compounds interact covalently with this ubiquitin ligase substrate adaptor. Structural information suggests that certain drugs acting on C151 may disrupt the interaction with CUL3-RBX1 (REfS 273, 274 ), thus leaving the KEAP1 pool saturated with bound NRF2 and allowing newly synthesized NRF2 to evade degradation: this was demonstrated using the model electrophile N-iodoacetyl-N-biotinylhexylenediamine 275 . Other compounds may modify KEAP1 in a way that it is no longer capable of interacting with NRF2 at both the high-affinity and low-affinity sites within the transcription factor. Notably, some electrophilic NRF2 activators, such as the cyclic cyanoenones, bind to thiols covalently but do not form irreversible adducts 276, 277 . Consequently, they combine the desirable features of both irreversible covalent drugs (that is, high potency and sustained target engagement), as well as that of reversible non-covalent drugs (that is, absence of permanent modification and therefore possible destruction or immunogenicity of their protein targets) 278 . A potential drawback of such molecules is that they might react with redox-sensitive cysteines in proteins other than KEAP1, hence compromising their function. The issue of specificity of thiolreactive molecules indicates that the window that allows for therapeutically relevant KEAP1 modification in the absence of thiol modifications within other proteins needs to be determined for each compound (fig. 1b) . Such www.nature.com/nrd a hierarchical presentation of target cysteines within KEAP1 as well as other thiol-containing non-target proteins has been termed the 'cysteine code' 279 and is influenced by both the chemistry and dose of inducer 280 . An important potential advantage of KEAP1-NRF2 PPI inhibitors is improved target selectivity. However, off-target effects cannot be completely excluded a priori for any small molecule. In addition, KEAP1 targets proteins other than NRF2 (REf. 281 ) for ubiquitylation, and these might also be affected. One of the few types of PPI inhibitor for which off-target selectivity has been evaluated are the potent mono-acidic sulfonamides; for example, compound 14 appeared to be fairly selective for KEAP1, showing modest activity in a GlaxoSmithKline enhanced cross-screen panel of in vitro assays to identify potential off-target effects 246 .
Animal models. A problem that precludes successful drug development for most chronic diseases is the incomplete reproducibility of human pathologies in animal models 282 . This issue may be associated with the lack of a very important hallmark of human degenerative diseases -namely, the progressive loss of homeostatic functions associated with NRF2. In fact, although much work still needs to be done in humans, evidence from animal studies indicates that NRF2 activity declines with ageing and that the pharmacological or genetic upregulation of NRF2 increases lifespan and improves health span 283, 284 . The lack of an 'NRF2 variable' in animal models of chronic diseases is well exemplified in murine models of AD. The current models are based on the assumption that expression of toxic APP or tau mutant proteins in an otherwise healthy animal background replicates the human pathology. Although these models provide valuable information about the onset and progression of the proteinopathy, they have systematically failed to translate therapeutic success to humans. The reasons for this failure may be related to the fact that these models do not consider the disease-related decline of homeostatic functions such as those related to NRF2. More sophisticated preclinical models will require a reverse translational approach in which not only the anatomopathological features of a specific disease are replicated in animals, but also the compromised redox, inflammatory or protein homeostasis. Thus, the NRF2-knockout mouse shares many alterations in common with patients with AD or even aged individuals 156 . Recent studies have demonstrated that compared with wild-type animals, NRF2-knockout mice fed a high-fat diet display greater neurovascular dysfunction, blood-brain barrier disruption, neuroinflammation, amyloidogenic gene expression and cognitive decline, mimicking many of the phenotypic changes that occur with ageing 285 . The introduction of low NRF2 expression as a variable to reduce homeostatic responses may be useful to improve current models of chronic diseases towards better therapeutic outcomes. Considering the slow decline of NRF2 activity with ageing, the heterozygous Nfe2l2 +/− mouse might be a suitable model to replicate both reduced basal expression and pharmacological upregulation.
Cancer risk. From a pharmacological point of view, it is necessary to determine how significant is the risk posed by increasing NRF2 levels beyond a safe threshold of causing cancer (fig. 4) . The impact of somatic mutations that promote NRF2 stability in cancer cells is markedly different from that caused by pharmacological activation of NRF2. Thus, somatic mutations in KEAP1 and NFE2L2 result in high, unrestrained NRF2 activity, which is entirely distinct from the pulsatile activation caused by pharmacological administration of NRF2 activators. Kinetic features such as amplitude and areas under the curve, reflecting intensity and duration of NRF2 signalling, are vastly different in settings of activation by genetic versus pharmacological means 202, 286 . Moreover, gene loss or inactivating mutations in KEAP1 do not appear to have the same effect as pharmacological inhibition of this protein. Thus, KEAP1 loss increased the levels of NRF2 but also several oncogenic targets of this E3 ligase adaptor, including IKKβ and B cell lymphoma 2 (BCL-2), which might be at least partially responsible for malignant transformation. Accordingly, in a panel of cell lines with functional KEAP1, a well-established NRF2 activator, the BARD analogue RTA-405, increased NRF2 but not IKKβ or BCL-2 levels and did not confer a growth or survival advantage to tumour cells 287 .
Although at the present time a cancer risk from NRF2 activators cannot be dismissed, it is encouraging to see that a meta-analysis of a phase III trial of DMF has shown no difference in the cancer rate between the placebo and DMF-treated groups 288 . It is also important to note that some NRF2-activating drugs may reduce this risk if they have additional targets with antitumour effects. Thus, DMF was recently found to inhibit GAPDH 289 , and it is possible that such inhibition may lead to an energetic crisis in highly glycolytic KRAS or BRAF mutant cancer cells, thus preventing tumour development as shown for vitamin C 290 .
Outlook
A hallmark of many chronic diseases is the loss of homeostatic responses such as redox signalling, metabolic flexibility, controlled inflammation and proteostasis. The multifactorial nature of these complex diseases could be targeted with one single hit at the transcription factor NRF2 as its activation elicits beneficial comprehensive, 'multi-target' and long-lasting cytoprotective effects. Slowly but steadily, biopharmaceutical companies are developing drugs that target KEAP1, the main regulator of NRF2, although the peculiarity of the KEAP1-NRF2 system makes this approach particularly challenging for monitoring target engagement and off-target effects. In addition, the concern about an increased cancer risk needs to be definitively excluded. Over the next few years, the ongoing clinical trials will undoubtedly provide important advances in answering these questions.
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